Antiger Therapeutics landed $272,503 SBIR grant from the National Institute of Allergy and Infectious Disease, one of the National Institutes of Health, to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects.
According to filings with the Missouri Secretary of States website Antiger was incorporated Feb. 10, 2022 with Hongjie Guo as registered agent. The NIH award site identifies Guo as the CEO. Its address is 4340 Duncan, in the Cortex Innovation Community in St. Louis.
Antibody-mediated rejection (AMR) is a leading cause of graft failure among transplant recipients and is associated with high mortality rates and increased healthcare costs. Through this SBIR funding, Antiger says it will develop a novel biologic therapy with antigen-specific precision to remove the root cause of most AMR cases and prolong graft function. In the SBIR project documentation they predict the ultimate product of this project should improve the well-being, quality of life, and survival of transplant recipients while reducing the infection risk and need for re- transplantation and organ demand.
